Explore the future of cholesterol management with cutting-edge pharmacologic therapies and the latest research on lipid-lowering treatments. Understand the transformative impact of AI in primary cardiovascular disease prevention, as highlighted by groundbreaking trials like TRANSFORM. Stay informed on how emerging therapies can help patients achieve optimal LDL-C levels and reduce cardiovascular risks.
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Faculty:
Deepak L. Bhatt, MD, MPH, MBA, FACC, FAHA, FESC, MSCAI
Director, Mount Sinai Fuster Heart Hospital
Dr. Valentin Fuster Professor of Cardiovascular Medicine
Icahn School of Medicine at Mount Sinai
New York, NY
Dr. Bhatt has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Angiowave, Bayer, Boehringer Ingelheim Pharmaceuticals, Inc., CellProthera, Cereno Scientific, GlaxoSmithKline, Hims & Hers Health, Inc., Janssen Biotech, Inc., Merck, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio Pharmaceuticals, Inc., PLx Pharma, SFJ Pharmaceuticals, Stasys Medical Corporation, Youngene Therapeutics
Contracted Research: 89Bio, Abbott, Acesion Pharma, Afimmune, Aker Biomarine, Alnylam Pharmaceuticals, Inc, Amarin Corporation plc, Amgen Inc., AstraZeneca Pharmaceuticals LP, Bayer, Beren, Biotronik, Boehringer Ingelheim Pharmaceuticals, Inc., Boston Scientific, Bristol Myers Squibb Company, Cardax, CellProthera, Cereno Scientific, Chiesi, CinCor Pharma, Inc., Cleerly, CSI, CSL Behring, Eisai Co., Ltd., Endotronix, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia Pharmaceuticals, Inc., Ironwood Pharmaceuticals, Inc., Ischemix, Inc., Janssen Biotech, Inc., Javelin, Lexicon Pharmaceuticals, Inc., Lilly, Medtronic, Inc., Merck, Moderna, Inc., MyoKardia, NirvaMed, Novartis, Novo Nordisk, Otsuka Pharmaceutical Co., Ltd., Owkin, Pfizer, Inc., PhaseBio Pharmaceuticals, Inc., Philips, PLx Pharma, Recardio, Regeneron Pharmaceuticals, Inc., Roche, Sanofi, SpectraWAVE, Stasys Medical Corporation, Synaptics, The Medicines Company, Vascular Solutions, Youngene Therapeutics
Patent Beneficiary: Lexicon Pharmaceuticals, Sotagliflozin
Stock Options: Angiowave, Bristol Myers Squibb Company
Marc P. Bonaca, MD, MPH
Director, Vascular Research
Associate Professor of Medicine
University of Colorado School of Medicine
Aurora, CO
Dr. Bonaca has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: AstraZeneca, Bayer, Merck, Roche Diagnostics
Matthew J. Budoff, MD, FACC, FAHA
Investigator, The Lundquist Institute
Professor of Medicine
David Geffen School of Medicine at UCLA
Torrance, CA
No relevant relationships reported
David J. Maron, MD
Director, Preventive Cardiology
C. F. Rehnborg Professor of Medicine
Stanford Medicine
Stanford, CA
No relevant relationships reported
Pam R. Taub, MD, FACC, FASPC
Director, Step Family Foundation Cardiovascular Rehabilitation and Wellness Center
Division of Cardiovascular Medicine
UC San Diego Health System
La Jolla, CA
Dr. Taub has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Amarin, Amgen, Bayer, Boehringer Ingelheim, Esperion, Medtronic, Novartis, Novo Nordisk, Sanofi
Ownership Interest: Epirium Bio
Reviewers/Content Planners/Authors:
After participating in this educational activity, participants should be better able to:
This activity is designed to meet the educational needs of cardiologists, primary care physicians, endocrinologists, and nephrologists, as well as nurses, physician assistants, nurse practitioners, pharmacists, and all other healthcare providers involved in managing patients with cardiovascular disease.
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 0.75 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until June 14, 2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 0.75 contact hours/.075 CEUs of pharmacy contact hours.
The Universal Activity Number for this program is JA0006235-0000-24-068-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME, LLC, is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care.
This activity is supported by independent educational grants from Cleerly Health, Esperion Therapeutics, Inc., and Lexicon Pharmaceuticals.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Total CME you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
Release Date:
Expiration Date:
